JP2000507828A - アルツハイマー病の診断および治療法 - Google Patents

アルツハイマー病の診断および治療法

Info

Publication number
JP2000507828A
JP2000507828A JP9535410A JP53541097A JP2000507828A JP 2000507828 A JP2000507828 A JP 2000507828A JP 9535410 A JP9535410 A JP 9535410A JP 53541097 A JP53541097 A JP 53541097A JP 2000507828 A JP2000507828 A JP 2000507828A
Authority
JP
Japan
Prior art keywords
amyloid
protein
peptide
growth factor
nerve growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9535410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000507828A5 (enExample
Inventor
ジルクレスト，バーバラ，エイ．
ヤール，ミーナ
Original Assignee
ザ トラスティーズ オブ ボストン ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ボストン ユニバーシティー filed Critical ザ トラスティーズ オブ ボストン ユニバーシティー
Publication of JP2000507828A publication Critical patent/JP2000507828A/ja
Publication of JP2000507828A5 publication Critical patent/JP2000507828A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
JP9535410A 1996-03-29 1997-03-28 アルツハイマー病の診断および治療法 Ceased JP2000507828A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62576596A 1996-03-29 1996-03-29
US08/625,765 1996-03-29
PCT/US1997/004966 WO1997037228A1 (en) 1996-03-29 1997-03-28 Methods for diagnosing and treating alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2000507828A true JP2000507828A (ja) 2000-06-27
JP2000507828A5 JP2000507828A5 (enExample) 2004-11-25

Family

ID=24507498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9535410A Ceased JP2000507828A (ja) 1996-03-29 1997-03-28 アルツハイマー病の診断および治療法

Country Status (8)

Country Link
US (3) US6242416B1 (enExample)
EP (1) EP0890105B1 (enExample)
JP (1) JP2000507828A (enExample)
AT (1) ATE346303T1 (enExample)
AU (1) AU719038B2 (enExample)
CA (1) CA2250075C (enExample)
DE (1) DE69736976T2 (enExample)
WO (1) WO1997037228A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525095A (ja) * 2013-07-09 2016-08-22 ニューロ−バイオ リミテッドＮｅｕｒｏ−Ｂｉｏ Ｌｔｄ 神経変性疾患
JP2019178148A (ja) * 2014-05-28 2019-10-17 テクニスチェ ユニベルシタト ドレスデン 免疫療法のための医薬の組合わせ
JP2022066234A (ja) * 2017-03-06 2022-04-28 リュー，ジュン Ａβ誘導性損傷抑制又は軽減剤

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867179B1 (en) 1994-08-31 2005-03-15 Trustees Of Boston University Methods of inducing hair growth and coloration
US7196055B2 (en) * 1994-08-31 2007-03-27 Trustees Of Boston University Inhibition of apoptosis in keratinocytes by a ligand of p75 nerve growth factor receptor
DE69736976T2 (de) 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
CN1377276A (zh) * 1999-08-09 2002-10-30 特里帕普股份公司 含有三肽的药用组合物
KR20020007432A (ko) * 2000-07-13 2002-01-29 박현석 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약
US6593455B2 (en) * 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
EP1436317A1 (en) * 2001-09-19 2004-07-14 Tripep Ab Molecules that block viral infectivity and methods of use thereof
AUPS230702A0 (en) * 2002-05-14 2002-06-13 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
PL378163A1 (pl) * 2003-02-21 2006-03-06 Tripep Ab Pochodna glicynoamidu do hamowania replikacji HIV
US20050096319A1 (en) * 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
JP2007528202A (ja) * 2003-03-28 2007-10-11 株式会社インテレクチャル・プロパティ・コンサルティング 神経再生のための組成物および方法
JP4769709B2 (ja) * 2003-05-08 2011-09-07 ディーエスエム アイピー アセッツ ビー．ブイ． 皮膚の構造を改善するために美容上適用するためのトリペプチドおよびその誘導体
US7608586B2 (en) * 2003-06-11 2009-10-27 The University Of Rochester Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
WO2006113097A2 (en) * 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
WO2006116400A2 (en) * 2005-04-27 2006-11-02 Massachusetts Institute Of Technology Promoter engineering and genetic control
CN101605554A (zh) * 2006-10-23 2009-12-16 国立大学法人名古屋大学 脑内氧化抑制剂及其应用
EP2376120A2 (en) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
US9458427B2 (en) * 2009-08-07 2016-10-04 Case Western Reserve University IFNγR2 compositions and methods of inhibiting neuronal cell death
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
BR112012009997A2 (pt) * 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP2542571B1 (en) * 2010-03-03 2016-05-25 The University of British Columbia Oligomer-specific amyloid beta epitope and antibodies
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
ES2628596T3 (es) 2010-11-29 2017-08-03 Akershus Universitetssykehus Procedimientos y composiciones para monitorizar la actividad fagocítica
EP2764120B1 (en) * 2011-10-05 2020-06-10 Blanchette Rockefeller Neurosciences, Institute Stimulus-elicited genomic profile markers of a neurodegenerative condition
US9534016B2 (en) * 2011-11-28 2017-01-03 Buck Institute For Research On Aging Netrin loop peptide mimetics and uses thereof
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP6359160B2 (ja) * 2017-07-25 2018-07-18 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN119661638B (zh) * 2024-11-22 2025-07-18 象山县第一人民医院医疗健康集团(宁波市第四医院、宁波市第四医院医院管理研究所) 一种修复神经损伤的多肽、制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4918405A (en) * 1988-10-26 1990-04-17 Hewlett-Packard Company Signal generator utilizing a combined phase locked and frequency locked loop
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
IL101661A (en) * 1991-04-23 1998-02-08 Regeneron Pharma Method for detecting, identifying or measuring agents having neurotrophin activity
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5576209A (en) 1994-10-24 1996-11-19 The Regents Of The University Of California Method for increasing the resistance of neural cells to β-amyloid peptide toxicity
DE69736976T2 (de) * 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525095A (ja) * 2013-07-09 2016-08-22 ニューロ−バイオ リミテッドＮｅｕｒｏ−Ｂｉｏ Ｌｔｄ 神経変性疾患
JP2019178148A (ja) * 2014-05-28 2019-10-17 テクニスチェ ユニベルシタト ドレスデン 免疫療法のための医薬の組合わせ
JP2022066234A (ja) * 2017-03-06 2022-04-28 リュー，ジュン Ａβ誘導性損傷抑制又は軽減剤
JP7417217B2 (ja) 2017-03-06 2024-01-18 リュー，ジュン Ａβ誘導性損傷抑制又は軽減剤

Also Published As

Publication number Publication date
US20020051988A1 (en) 2002-05-02
WO1997037228A1 (en) 1997-10-09
EP0890105A1 (en) 1999-01-13
CA2250075C (en) 2008-06-10
DE69736976D1 (de) 2007-01-04
EP0890105B1 (en) 2006-11-22
US6242416B1 (en) 2001-06-05
AU2424597A (en) 1997-10-22
ATE346303T1 (de) 2006-12-15
AU719038B2 (en) 2000-05-04
DE69736976T2 (de) 2007-10-18
US20040254110A1 (en) 2004-12-16
US6696303B2 (en) 2004-02-24
CA2250075A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
EP0890105B1 (en) Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US6960559B1 (en) Neurite growth regulatory factors
JP6920324B2 (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
US6103232A (en) Neurite growth regulatory factors
US20150023971A1 (en) Modulation of Activity of Proneurotrophins
da Rocha et al. APP binds to the EGFR ligands HB-EGF and EGF, acting synergistically with EGF to promote ERK signaling and neuritogenesis
WO1994009808A1 (en) Substances having the growth-promoting effect of amyloid precursor protein
WO1998022499A2 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO1998022499A9 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
EP0716591B1 (en) USE OF ApoE FOR BINDING TAU AND MAP2c PROTEINS AND FOR TREATING ALZHEIMER'S DISEASE
US7790673B2 (en) Methods and compositions relating to cystatin C
JP2008096311A (ja) 新規のアルツハイマー病検出方法
AU2002363524B2 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
AU2002246766B2 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof
US20040266677A1 (en) Method of diagnosing and treating lens illnesses using human HSF4 gene and coded product thereof
AU2002363524A1 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
WO2006075172A2 (en) Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
KR101634855B1 (ko) Trpc3와 trpc1 간의 이형복합체 형성을 저해하는 물질을 이용한 칼슘이온 관련 근육 질환의 예방 또는 치료용 조성물
Tanik The interplay between Lewy body-like alpha-synuclein aggregates and protein degradation pathways in a cell-based model of Parkinson's disease
AU2002246766A1 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof
CA2221391A1 (en) Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070417

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071016